Table 2 Weighted analysis of survival by conditioning regimen of patients in CR1 and CR2.

From: Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study

Outcome

Strata

n

Day 100 (95% CI)

1 year (95% CI)

3 years (95% CI)

5 years (95% CI)

HR

95% CI

P value*

CR1 (n = 1483)

 OS

FTBI

1271

81.8 (79.7–83.8)

72.5 (70.1–75.0)

68.8 (66.3–71.5)

1.00

0.25

CC

212

83.2 (80.7–85.8)

77.1 (74.2–80.0)

74.1 (71.1–77.3)

0.79

0.53–1.17

 LFS

FTBI

1271

74.7 (72.4–77.0)

65.8 (63.3–68.5)

63.8 (61.2–66.5)

1.00

0.83

CC

212

75.4 (72.5–78.4)

65.5 (62.3–68.9)

61.4 (58.0–64.9)

1.03

0.76–1.41

 RI

FTBI

1271

13.9 (12.1–16.1)

20.9 (18.7–23.4)

22.4 (20.1–25.0)

1.00

0.33

CC

212

16.9 (11.3–25.3)

24.9 (17.9–34.5)

26.9 (19.7–36.9)

1.20

0.83–1.71

 NRM

FTBI

1271

11.4 (9.7–13.3)

13.3 (11.5–15.4)

13.8 (11.9–15.9)

1.00

0.47

CC

212

7.7 (4.1–14.7)

9.6 (5.5–17.0)

11.7 (6.9–19.8)

0.79

0.41–1.50

 aGvHD III–IV

FTBI

1225

11.8 (10.1–13.7)

1.00

0.16

CC

207

16.9 (10.7–26.7)

1.46

0.86–2.50

 cGvHD

FTBI

1123

20.0 (17.6–22.6)

23.3 (20.9–26.1)

24.3 (21.8–27.1)

1.00

0.60

CC

189

18.5 (11.8–29.1)

20.8 (13.7–31.4)

20.8 (13.7–31.4)

0.86

0.50–1.48

 cGvHD ext.

FTBI

1107

8.2 (6.7–10.0)

10.4 (8.7–12.4)

11.3 (9.5–13.4)

1.00

0.54

CC

189

6.5 (3.1–13.8)

8.2 (4.3–15.9)

8.2 (4.3–15.9)

0.82

0.42–1.58

CR2 (n = 1549)

 OS

FTBI

1339

73.1 (70.8–75.4)

61.9 (59.4–64.5)

58.8 (56.2–61.6)

1.00

<0.0001

CC

210

61.0 (58.1–64.1)

44.1 (41.1–47.4)

35.9 (33.0–39.1)

1.75

1.36–2.27

 LFS

FTBI

1339

65.1 (62.6–67.6)

55.5 (52.9–58.2)

53.7 (51.1–56.5)

1.00

<0.0001

CC

210

45.9 (43.0–49.1)

34.2 (31.3–37.3)

29.4 (26.6–32.5)

1.80

1.43–2.25

 RI

FTBI

1339

21.9 (19.7–24.3)

29.5 (27.0–32.2)

30.6 (28.1–33.3)

1.00

<0.0001

CC

210

35.4 (27.3–45.9)

45.6 (36.8–56.5)

49.3 (40.3–60.2)

1.96

1.44–2.67

 NRM

FTBI

1339

13.0 (11.3–15.0)

15.0 (13.2–17.2)

15.7 (13.8–17.9)

1.00

0.044

CC

210

18.7 (12.7–27.4)

20.2 (14.1–29.0)

21.3 (15.1–30.2)

1.51

1.01–2.25

 aGvHD III–IV

FTBI

1274

13.1 (11.4–15.1)

1.00

0.36

CC

204

10.6 (6.5–17.2)

0.80

0.51–1.28

 cGvHD

FTBI

1192

17.9 (15.7–20.4)

20.5 (18.1–23.1)

21.2 (18.8–23.9)

1.00

0.064

CC

184

25.3 (17.7–36.2)

25.8 (18.1–36.7)

26.0 (18.3–36.9)

1.52

0.98–2.37

 cGvHD ext.

FTBI

1178

7.5 (6.1–9.3)

9.6 (8.0–11.5)

9.9 (8.3–11.9)

1.00

0.075

CC

184

9.5 (5.7–16.1)

10.0 (6.0–16.5)

10.1 (6.2–16.7)

1.64

0.95–2.84

  1. a/cGvD acute/chronic graft versus host disease, CC chemotherapy-based conditioning, CI confidence interval, CR1 first complete remission, CR2 second complete remission, ext. extensive, FTBI fractionated total body irradiation, HR Hazard ratio, LFS leukemia-free survival, NRM nonrelapse mortality, OS overall survival, RI relapse incidence.
  2. *Wald test in a weighted Cox model taking into account the center effect (cause specific for RI, NRM, and GvHD outcomes).